Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphomaAnnie Xiao, Matthew Mei, Elizabeth Budde et al.|Leukemia & lymphoma/Leukemia and lymphoma|2025Cited by 3
High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.Steven T. Rosen, Nishita Matangi, Murali Janakiram et al.|Blood|2025Cited by 1
Bispecific Antibody Treatment for Diffuse Large B Cell Lymphoma, a Real-World Evidence (RWE) StudyGeoffrey Shouse, Alexey V. Danilov, Lu Chen et al.|Transplantation and Cellular Therapy|2025Cited by 0